Form 4: Generation Bio Co. CFO Awarded Stock Options

Generation Bio Co.'s Chief Financial Officer, Kevin John Conway, was granted stock options for 355,260 shares on January 10, 2025.

Summary

• Kevin John Conway, the Chief Financial Officer of Generation Bio Co., was granted stock options to purchase 355,260 shares of the company's common stock.
• The options were granted on January 10, 2025, with an exercise price of $0.926 per share.
• The options vest over four years, with 25% vesting on January 10, 2026, and the remaining shares vesting in equal quarterly installments thereafter.
• The options expire on January 9, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating executives in the biotech industry.
• The vesting schedule of four years with a cliff at one year followed by quarterly vesting is a typical structure for such grants.
• Companies like Amgen, Gilead, and Biogen also use stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view this positively as it incentivizes the CFO to work towards increasing the company's value.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, equity, vesting, Generation Bio Co., GBIO, CFO